Abbisko Cayman Limited (HKG:2256)
Hong Kong
· Delayed Price · Currency is HKD 13.22
-0.39 (-2.87%)
Apr 29, 2026, 4:08 PM HKT
Abbisko Cayman Revenue
In the year 2025, Abbisko Cayman had annual revenue of 612.12M CNY with 21.45% growth.
Revenue
612.12M CNY
Revenue Growth
+21.45%
P/S Ratio
13.46
Revenue / Employee
2.71M CNY
Employees
226
Market Cap
9.17B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Lepu Biopharma | 1.04B |
| Alphamab Oncology | 630.11M |
| HBM Holdings | 1.23B |
| CARsgen Therapeutics Holdings | 139.84M |
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Everest Medicines | 1.90B |